MannKind Corporation (NASDAQ:MNKD) on Feb. 18 reported financial results for the fourth quarter and full year ended December 31, 2013. The net loss applicable to common stockholders for fiscal year 2013 was $(191.5) million, or $(0.64) per share based on 299.6 million weighted average shares outstanding, compared with a net loss applicable to common stockholders of $(169.4) million, or $(0.94) per share based on 180.9 million weighted average shares outstanding for fiscal year 2012. MannKind Corporation (NASDAQ:MNKD) stock performance was 0.71% in last session and finished the day at $5.69. Traded volume was 19.30 million shares in the last session and the average volume of the stock remained 6.63 million shares. The beta of the stock remained 1.77. MannKind Corporation (NASDAQ:MNKD) insider ownership is 0.60%.

Inovio Pharmaceuticals Inc. (NYSEMKT:INO) on Mar. 17 reported financial results for the fourth quarter and year ended Dec. 31, 2013. Inovio Pharmaceuticals Inc. (NYSEMKT:INO) rose 11.37% to $3.82 yesterday on volume of 14.37 million shares. The intra-day range of the stock was $3.43 – $3.85. Inovio Pharmaceuticals Inc. (NYSEMKT:INO) has a market capitalization of 733.27 million.

Ryan & Maniskas, LLP announces that a class action lawsuit has been filed in the United States District Court for the District of Oregon on behalf of a class comprising all purchasers of Galena Biopharma, Inc. (NASDAQ:GALE). Galena Biopharma Inc. (NASDAQ:GALE)’s stock on March 19, 2014 reported a higher of 9.22% to the closing price of $3.08. Its fifty two weeks range is $1.65 – $7.77. The total market capitalization recorded 268.95 million. The overall volume in the last trading session was 9.07 million shares. In its share capital, Galena Biopharma Inc. (NASDAQ:GALE) has 87.32 million outstanding shares.

Brower Piven, A Professional Corporation on Mar. 18 announced that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of purchasers of Geron Corporation (NASDAQ:GERN) securities during the period between June 16, 2013 and March 11, 2014, inclusive (the “Class Period”). On Wednesday, shares of Geron Corporation (NASDAQ:GERN) dropped -8.06% to close the day at $2.28. Company return on investment (ROI) is -83.80% and its monthly performance is recorded as -56.15%. Geron Corporation (NASDAQ:GERN) quarterly revenue growth is -52.99%.